SFT2D1 Inhibitors
Chemical inhibitors of SFT2D1 disrupt its function through various mechanisms centered on the protein's role in vesicular trafficking and glycosylation processes. Benzylpenicillin acts by impairing the glycosylation of SFT2D1 in the Golgi apparatus, a process essential for its function in vesicular transport. Similarly, Tunicamycin hinders N-linked glycosylation, a pathway crucial for protein folding and function, thereby affecting the maturation state of SFT2D1. Brefeldin A targets the protein's trafficking capabilities by inhibiting the activation of ADP-ribosylation factors, leading to a blockade of ER to Golgi transport. Monensin, as an ionophore, disrupts the ionic homeostasis within the Golgi, which is critical for SFT2D1's role in vesicular trafficking. Dynasore contributes to the inhibition by preventing vesicle scission from the Golgi, thereby directly impacting the vesicular transport processes facilitated by SFT2D1.
The second set of inhibitors operates by targeting the cytoskeleton and enzymatic activities related to SFT2D1 function. Nocodazole disrupts microtubule polymerization, which is essential for vesicular transport, consequently inhibiting the role of SFT2D1 in this process. Cytochalasin D impairs actin polymerization, affecting the integrity of the cytoskeleton and vesicular movement, which are vital for SFT2D1's trafficking functions. Golgicide A specifically inhibits GBF1, a regulator in vesicular trafficking, thus disrupting the transport processes related to SFT2D1. IL-1beta induces ER stress that may disrupt protein trafficking and folding machinery, affecting SFT2D1's function. Inhibitors like Swainsonine, Castanospermine, and Deoxynojirimycin target the glycosylation pathway by inhibiting enzymes like alpha-mannosidase II and glucosidases, which are essential for the glycosylation and proper folding of SFT2D1, thereby impairing its trafficking capabilities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which is required for the proper folding and function of many membrane and secreted proteins. Inhibition of this process can disrupt the maturation and function of SFT2D1. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER to Golgi trafficking by blocking the activation of ADP-ribosylation factors. As SFT2D1 is involved in vesicular transport processes, its function can be inhibited by such a disruption. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin acts as an ionophore that disrupts Golgi function by altering pH and ion gradients. This interferes with vesicular trafficking and can inhibit the function of SFT2D1, which is involved in trafficking processes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a dynamin inhibitor that impedes vesicle scission from the Golgi, affecting the trafficking of proteins. Inhibiting this step can functionally inhibit SFT2D1 by preventing the vesicular transport it facilitates. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is essential for vesicle transport in cells. By disrupting microtubules, Nocodazole can functionally inhibit SFT2D1's role in vesicular trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D inhibits actin polymerization, which is crucial for maintaining cytoskeleton integrity and vesicular movement. Inhibition of actin polymerization can, therefore, inhibit the vesicular trafficking functions of SFT2D1. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits the Golgi BFA resistance factor 1 (GBF1), a key regulator in vesicular trafficking. By inhibiting GBF1, Golgicide A can functionally inhibit SFT2D1 by disrupting its vesicular transport processes. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of alpha-mannosidase II, an enzyme involved in the processing of N-linked oligosaccharides in glycoproteins. Inhibition of this enzyme can impair SFT2D1's glycosylation and its associated trafficking functions. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidases involved in the N-linked glycosylation pathway. By inhibiting these enzymes, it can disrupt the proper folding and function of SFT2D1. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidases that are crucial for N-linked glycosylation. This inhibition can compromise the maturation and function of SFT2D1 involved in vesicular trafficking and protein sorting. | ||||||